The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Treatment advances in Vitiligo: An Updated Review
Open accessAbstract
INTRODUCTION: Vitiligo is a common disorder of depigmentation caused by the progressive destruction of melanocytes that affects the skin, hair, and mucous membranes, clinically presenting as depigmented macules and leukotrichia. This condition, affecting millions of people worldwide, has a significant psychosocial burden on patients' quality of life, particularly in relation to skin colour. The etiopathogenesis of this disorder is obscure, but multiple factors contribute to the loss of melanocytes in the skin, like oxidative stress, inflammation, genetics, and autoimmunity. The treatment of vitiligo has been challenging over the past years, but recent developments in understanding the etiopathogenesis of the disease have paved the way for the development of more effective and promising therapeutic treatment options. OBJECTIVE: The aim of this review was to provide an overview of the underlying mechanisms and highlight the latest advances in the treatment of vitiligo. METHODOLOGY: This review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Metanalyses) guidelines. A comprehensive search of the literature was carried out through the PubMed electronic database from inception to 31 December 2023 using the following search terms "vitiligo" AND "JAK inhibitors", "vitiligo" AND "prostaglandin", " vitiligo" AND " afamelanotide", "vitiligo" AND "antioxidants", "vitiligo" AND "vitamin D3", "vitiligo" AND "statins", "vitiligo" AND "TNF-alpha", "vitiligo" AND "interleukin", "vitiligo" AND "light therapy". Two independent reviewers screened titles, abstracts, and full texts to select papers dealing with vitiligo and its treatment. CONCLUSION: The advent of treatment modalities like Janus kinase inhibitors, prostaglandin analogues, antioxidants, TNF-α inhibitors, targeted phototherapy, and excimer lasers has revolutionized the therapeutic possibilities, offering a ray of hope to the individuals suffering from this devastating condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Narrowband UVB phototherapy is a cornerstone modality that promotes melanocyte proliferation, migration from hair follicles, and immunomodulation by suppressing pathogenic T-cell responses.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combination therapies, particularly JAK inhibitors with phototherapy, appear to enhance efficacy and durability of response.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conventional treatments such as topical corticosteroids and calcineurin inhibitors remain first-line for reducing local inflammation and halting disease progression.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Advances in understanding the interferon-γ/JAK-STAT axis have led to clinical use of JAK inhibitors in vitiligo, most notably with topical ruxolitinib for nonsegmental vitiligo, while systemic JAK inhibitors remain under investigation or off-label in many settings.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, modern vitiligo management is shifting toward targeted, mechanism-based interventions designed not only to induce repigmentation but also to maintain long-term disease control [53,54].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bergqvist, C., & Ezzedine, K. (2020) · Dermatology · doi:10.1159/000506103 · Cited by 799
Ezzedine, K., Lim, H. W., Suzuki, T., Katayama, I., Hamzavi, I. H., Lan, C.-C. E., Goh, B. K., Anbar, T. S., de Catro, C. C. S., Lee, A. Y., et al. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00997.x · Cited by 701
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594735 · Cited by 406
Roy, T., Boateng, S. T., Uddin, M. B., Banang‐Mbeumi, S., Yadav, R. K., Bock, C. R., Folahan, J. T., Siwe‐Noundou, X., Walker, A. L., King, J. A. C., et al. (2023) · Cells · doi:10.3390/cells12121671 · Cited by 183
Lambert, C., Zappia, J., Sanchez, C., Florin, A., Dubuc, J., & Henrotin, Y. E. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.607186 · Cited by 180
Ezzedine, K., Peeva, E., Yamaguchi, Y., Cox, L. A., Banerjee, A., Han, G., Hamzavi, I. H., Ganesan, A. K., Picardo, M., Thaçi, D., et al. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.11.005 · Cited by 169
The Role of Oxidative Stress in the Pathogenesis of Vitiligo: A Culprit for Melanocyte Death
Xuan, Y., Yang, Y., Xiang, L. F., & Zhang, C. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8498472 · Cited by 158
Richmond, J. M., Strassner, J. P., Rashighi, M., Agarwal, P., Garg, M., Essien, K. I., Pell, L., & Harris, J. E. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.032 · Cited by 155
Comorbidities in vitiligo: comprehensive review
Dahir, A. M., & Thomsen, S. F. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14055 · Cited by 148
Mohammad, T. F., Al-Jamal, M., Hamzavi, I. H., Harris, J. E., Leone, G., Cabrera, R., Lim, H. W., Pandya, A. G., & Esmat, S. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.041 · Cited by 138
Spritz, R. A., & Santorico, S. A. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.004 · Cited by 135
Prevalence of Vitiligo Among Adults in the United States
Gandhi, K., Ezzedine, K., Anastassopoulos, K. P., Patel, R., Sikirica, V., Daniel, S. R., Napatalung, L., Yamaguchi, Y., Baik, R., & Pandya, A. G. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.4724 · Cited by 130
Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid
Tóth, F., Cseh, E. K., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010403 · Cited by 105
Advances in vitiligo: Update on therapeutic targets
Feng, Y., & Lu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986918 · Cited by 103
Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art
Diotallevi, F., Gioacchini, H., SIMONI, E. D., Marani, A., Candelora, M., Paolinelli, M., Molinelli, E., Offidani, A., & Simonetti, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054910 · Cited by 102
Updates and new medical treatments for vitiligo (Review)
Kubelis‐López, D. E., Zapata‐Salazar, N. A., Said‐Fernández, S., Sanchez-Dominguez, C. N., Salinas-Santander, M. A., Martínez-Rodríguez, H. G., Vázquez‐Martínez, O., Wollina, U., Lotti, T., & Ocampo‐Candiani, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10229 · Cited by 91
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors
Cunningham, K. N., & Rosmarin, D. M. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00752-6 · Cited by 91
Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review
Białczyk, A., Wełniak, A., Kamińska, B., & Czajkowski, R. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00672-z · Cited by 87
Vitiligo, From Physiopathology to Emerging Treatments: A Review
Migayron, L., Boniface, K., & Sénéschal, J. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00447-y · Cited by 82
The convergence theory for vitiligo: A reappraisal
Kundu, R. V., Mhlaba, J. M., Rangel, S. M., & Poole, I. C. L. (2018) · Experimental Dermatology · doi:10.1111/exd.13677 · Cited by 76
Abdallah, M., El-Mofty, M. A., Anbar, T. S., Rasheed, H. M., Esmat, S. M., Al‐Tawdy, A., Fawzy, M. M., Abdel-Halim, D. M., Hegazy, R. A., Gawdat, H. I., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12667 · Cited by 67
Topical ruxolitinib: A new treatment for vitiligo
Tavoletti, G., Avallone, G., Conforti, C., Roccuzzo, G., Maronese, C. A., Mattioli, M. A., Quaglino, P., Zalaudek, I., Marzano, A. V., Ribero, S., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19162 · Cited by 67
Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments
Custurone, P., Bartolomeo, L. D., Irrera, N., Borgia, F., Altavilla, D., Bitto, A., Pallio, G., Squadrito, F., & Vaccaro, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111429 · Cited by 61
Oparaugo, N. C., Ouyang, K., Nguyen, N. P. N., Nelson, A. M., & Agak, G. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021527 · Cited by 60
Nada, H. R., Sharkawy, D. A. E., Elmasry, M. F., Rashed, L. A., & Mamdouh, S. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1792-6 · Cited by 54
The Role of TRM Cells in the Pathogenesis of Vitiligo—A Review of the Current State-Of-The-Art
Frączek, A., Owczarczyk-Saczonek, A. B., & Placek, W. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103552 · Cited by 54
New insight into the role of exosomes in vitiligo
Wong, P. M., Yang, L., Yang, L., Wu, H., Li, W., Ma, X., Katayama, I., & Zhang, H. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102664 · Cited by 53
Radi, G., Simonetti, O., Rizzetto, G., Diotallevi, F., Molinelli, E., & Offidani, A. (2021) · Healthcare · doi:10.3390/healthcare9111575 · Cited by 52
Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro
Dong, J., Huang, X., Ma, L.-P., Qi, F., Wang, S., Zhang, Z.-Q., Wei, S., Gao, L., & Liu, F. (2022) · Dose-Response · doi:10.1177/15593258221105370 · Cited by 52
Microneedling in vitiligo: A systematic review
Salloum, A., Bazzi, N., Maalouf, D., & Habre, M. (2020) · Dermatologic Therapy · doi:10.1111/dth.14297 · Cited by 47
Role of chemokines and the corresponding receptors in vitiligo: A pilot study
Yang, L., Yang, S., Lei, J., Hu, W., Chen, R., Lin, F., & Xu, A. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.14004 · Cited by 46
Roberts, G. H. L., Paul, S., Yorgov, D., Santorico, S. A., & Spritz, R. A. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.06.013 · Cited by 40
Yu, Z., & Wolf, P. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.08.004 · Cited by 40
Agarwal, K., Podder, I., Kassir, M., Vojvodić, A., Schwartz, R. A., Wollina, U., Valle, Y., Lotti, T., Rokni, G. R., Grabbe, S., et al. (2019) · Dermatologic Therapy · doi:10.1111/dth.13215 · Cited by 40
Levels of TNF-α, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo
Karagün, E., & Baysak, S. (2020) · The Aging Male · doi:10.1080/13685538.2020.1806814 · Cited by 39
Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
Elkady, A., Bonomo, L., Amir, Y., Vekaria, A. S., & Guttman‐Yassky, E. (2017) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.07.009 · Cited by 36
Kanti, V., Puder, L., Jahnke, I., Krabusch, P., Kottner, J., Vogt, A., Richter, C., Andruck, A., Lechner, L., Poitou, C., et al. (2021) · Skin Pharmacology and Physiology · doi:10.1159/000516282 · Cited by 36
Hamzavi, I. H., Rosmarin, D. M., Harris, J. E., Pandya, A. G., Lebwohl, M., Gottlieb, A. B., Butler, K. A., Kuo, F. I., Sun, K., & Grimes, P. E. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.05.047 · Cited by 36
Consensus on the treatment of vitiligo – Brazilian Society of Dermatology
Dellatorre, G., Antelo, D. A. P., Bedrikow, R. B., Cestari, T. F., Follador, I., Ramos, D. G., & de Castro, C. C. S. (2020) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2020.05.007 · Cited by 35
Integrating neuronal involvement into the immune and genetic paradigm of vitiligo
Abadie, M. A., & Gawkrodger, D. J. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14490 · Cited by 35
Pacifico, A., Damiani, G. B., Iacovelli, P., Conic, R. R. Z., Young Dermatologists Italian Network (YDIN), González, S., & Morrone, A. (2021) · Dermatologic Therapy · doi:10.1111/dth.14776 · Cited by 35
Biologic and targeted therapeutics in vitiligo
Karagaiah, P., Schwartz, R. A., Lotti, T., Wollina, U., Grabbe, S., & Goldust, M. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14770 · Cited by 29
Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib
Yagi, K., Ishida, Y., Otsuka, A., & Kabashima, K. (2021) · Australasian Journal of Dermatology · doi:10.1111/ajd.13572 · Cited by 28
Bimatoprost ophthalmic solution in facial vitiligo
Jha, A. K., Prasad, S., & Sinha, R. (2017) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.12443 · Cited by 26
A Systematic Review of Nutrition, Supplement, and Herbal-Based Adjunctive Therapies for Vitiligo
Shakhbazova, A., Wu, H., Chambers, C. J., & Sivamani, R. K. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2020.0292 · Cited by 22
Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
Abdou, A. G., Maraee, A. H., Yassien, H., & Sarhan, M. (2018) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2018.09.18 · Cited by 20
Alshiyab, D. M., Al‐Qarqaz, F., Muhaidat, J., Khader, Y. S., Al-Sheyab, R. F., & Jafaar, S. I. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1729952 · Cited by 19
Statins role in vitiligo: A mini-review
Al-Kuraishy, H. M., Hussian, N., Al-Naimi, M. S., & Al-Gareeb, A. I. (2020) · Turkish Journal of Dermatology · doi:10.4103/tjd.tjd_38_19 · Cited by 19
Liu, X., Yao, Z., Wang, Y., Chai, L., & Zhou, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108789 · Cited by 19
Management of Stable Vitiligo—A Review of the Surgical Approach
Grochocka, M., Wełniak, A., Białczyk, A., Marek‐Józefowicz, L., Tadrowski, T., & Czajkowski, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051984 · Cited by 18
Sun, Y., Guan, X., Wang, H., Zhang, J., Gu, H., Lü, H., Yao, Z., Chen, X. '., Zeng, F., Wu, Y., et al. (2020) · Dermatologic Therapy · doi:10.1111/dth.14610 · Cited by 17
Simvastatin and non‐segmental vitiligo: A new potential treatment option?
Shaker, E. S. E., Allam, S. H., Mabrouk, M. M., El-Gharbawy, N. M., & Salaam, S. F. A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15969 · Cited by 16
The role of cytokines and vitamin D in vitiligo pathogenesis
Beyzaee, A. M., Goldust, M., Patil, A. D., Rokni, G. R., & Beyzaee, S. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15272 · Cited by 15
Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo
Yang, R., Chen, S., Fu, S.-P., Zhao, D., Wan, W.-H., Yang, K., Lei, W., Yang, Y. C., Zhang, Q., & Zhang, T. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1293101 · Cited by 14
Li, C., Hu, Y., Mu, Z., Shi, L., Sun, X., Wang, X., Wang, Y., & Li, X. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2302064 · Cited by 14
Iwanowski, T., Szlązak, P., Zabłotna, M., Olszewska, B., & Sokołowska‐Wojdyło, M. (2021) · Advances in Dermatology and Allergology · doi:10.5114/ada.2021.108896 · Cited by 12
Uses of Polypodium leucotomos Extract in Oncodermatology
Calzari, P., Vaienti, S., & Nazzaro, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020673 · Cited by 12
The First Case of Ustekinumab-Associated Hair Repigmentation and a Proposed Mechanism of Action
Park, S. J., Ahn, G. R., Park, J. W., & Seo, S. J. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.3.300 · Cited by 10
Assessment of prostaglandin F2‐alpha (PGF2α) in lesional and nonlesional skin of vitiligo patients
Nagui, N. A. R., El‐Tartoushy, S. A., Rashed, L. A., & Elmasry, M. F. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16307 · Cited by 8
Selenium Level in Patients with Vitiligo: A Meta‐Analysis
Dai, T., Xiaoying, S., Li, X., Li, H., Zhou, Y., & Liang, B. (2020) · BioMed Research International · doi:10.1155/2020/7580939 · Cited by 7
Salem, M. W., Azim, A. A. A. E., & Galal, S. A. (2023) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15621 · Cited by 5
Gharib, K. M., Ibrahim, A. M., Sharkawi, Y. A. F. E., El-Megrab, N. A., & Attia, M. (2023) · PubMed Central · Cited by 5
Advances in the function of traditional medicine for vitiligo treatment
Liu, J., Li, J.-Y., Xu, J., Li, L., Wang, C., Yuan, S., Zhang, W., & Li, H. (2023) · Traditional Medicine Research · doi:10.53388/tmr20230815002 · Cited by 4
Assessment of Serum Level of Interleukin-17 in Patients with Vitiligo
Mikhael, N. W., Hamed, A. M., Elfallah, A. A., & Ahmed, A. A. (2021) · Benha Journal of Applied Sciences · doi:10.21608/bjas.2021.188835 · Cited by 3
Sohafy, M. A. M. E., Ghanem, B. M., Metwally, S. S., State, A. F., & Elshawaf, R. A. M. (2021) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2021.194064 · Cited by 3
Stiegler, J., & Brickley, S. (2020) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000589 · Cited by 1
Do, H. T. T., Nguyen, H. T. M., & Kanekura, T. (2023) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000326 · Cited by 1
Research works printed but not linked: 2
- Zahoor M, Shaukat S, Khan MS, Ahmad TJ. Comparison of efficacy and safety of 0.005% calcipotriol ointment versus 0.05% betamethasone dipropionate ointment versus calcipotriol plus betamethasone ointment for the treatment of vitiligo. J Pak Assoc Dermatol [Internet]. 2017;27(1):30-6. Available from: http://jpad.com.pk/index.php/jpad/article/view/1023
- Feng Y, Lu Y. Advances in vitiligo: Update on therapeutic targets. Front Immunol. 2022;13:986918. DOI: 10.3389/fimmu.2022.986918. PMID: 36119071. · DOI
Cited by
Sorted by citations
The Neuro‐Endocrinal Regulation in Vitiligo
Liu, W., Ma, W., Xue, X., & Li, S. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70029 · Cited by 9
Lipidome Complexity in Physiological and Pathological Skin Pigmentation
Bastonini, E., Kovacs, D., Maresca, V., Ottaviani, M., Nardo, A. D., Flori, E., Cardinali, G., & Briganti, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146785 · Cited by 7
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1
“Overall, modern vitiligo management is shifting toward targeted, mechanism-based interventions designed not only to induce repigmentation but also to maintain long-term disease control [53,54].”
Lee, Y.-J., & Hyun, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167721 · Cited by 1
From melanocyte loss to targeted therapy: A comprehensive review of vitiligo management
Dan, D. D., Prabitha, P., & Agalgave, V. C. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100111 · Cited by 1
Metadata
- Authors
- Binti Ismail, I., Jabeen Bhat, Y., & Shurjeel ul Islam, M.
- Affiliations
- Department of dermatology venereology and leprosy GMC Srinagar
- ORCID
- Jabeen Bhat, Yasmeen
- Venue
- Dermatology Practical & Conceptual
- Publisher
- Mattioli1885
- Published
- 2025-01-29
- Volume
- 15
- Issue
- 1
- Pages
- 4600
- ISSN
- 2160-9381 (ISSN-L)
- PMC
- PMC11928143
- OpenAlex
- W4406955572
- Cited by
- 15
- References
- 67
- Citations by year
- 2026: 7 · 2025: 8
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Dermatology Practical & Conceptual (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Health Sciences › Medicine › Dermatology › Hair Growth and Disorders
- Keywords
- vitiligo, depigmentation, melanocyte loss, vitiligo treatment, JAK inhibitors, prostaglandin analogues, afamelanotide, antioxidants, vitamin D3, statins, TNF-alpha inhibitors, interleukin inhibitors, targeted phototherapy, excimer laser, oxidative stress, autoimmunity, etiopathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
